HC Wainwright restated their buy rating on shares of FlexShopper (NASDAQ:FPAY – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a $2.50 price target on the financial services provider’s stock. FlexShopper Price Performance Shares of FlexShopper stock opened at $1.28 on Wednesday. The company has a […]

HC Wainwright reaffirmed their buy rating on shares of Enliven Therapeutics (NASDAQ:ELVN – Free Report) in a report issued on Tuesday, Benzinga reports. The firm currently has a $37.00 price objective on the stock. Several other equities analysts have also issued reports on ELVN. Robert W. Baird initiated coverage on Enliven Therapeutics in a report […]

HC Wainwright reiterated their buy rating on shares of Joby Aviation (NYSE:JOBY – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports. HC Wainwright currently has a $9.00 price objective on the stock. A number of other research firms have also recently commented on JOBY. JPMorgan Chase & Co. boosted […]

HC Wainwright restated their buy rating on shares of Genenta Science (NASDAQ:GNTA – Free Report) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $25.00 target price on the stock. Genenta Science Price Performance GNTA opened at $4.40 on Wednesday. Genenta Science has a 12-month low of $2.20 and […]

HC Wainwright restated their buy rating on shares of Immix Biopharma (NASDAQ:IMMX – Free Report) in a report released on Thursday, Benzinga reports. They currently have a $7.00 price target on the stock. Immix Biopharma Stock Performance Shares of NASDAQ:IMMX opened at $1.63 on Thursday. The stock’s 50-day simple moving average is $1.93 and its […]

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They currently have a $65.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 9.83% from the company’s […]

HC Wainwright reiterated their neutral rating on shares of Kezar Life Sciences (NASDAQ:KZR – Free Report) in a research note published on Wednesday morning, MarketBeat Ratings reports. Kezar Life Sciences Stock Performance NASDAQ:KZR opened at $0.80 on Wednesday. The firm has a market capitalization of $58.06 million, a PE ratio of -0.57 and a beta […]

HC Wainwright reaffirmed their buy rating on shares of PolyPid (NASDAQ:PYPD – Free Report) in a research note released on Wednesday morning, Benzinga reports. The brokerage currently has a $14.00 price target on the stock. PolyPid Price Performance Shares of NASDAQ PYPD opened at $3.59 on Wednesday. The firm’s 50-day simple moving average is $3.52 […]

HC Wainwright restated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research report released on Thursday morning, Benzinga reports. They currently have a $10.00 target price on the biopharmaceutical company’s stock. Separately, StockNews.com upgraded Lexicon Pharmaceuticals to a sell rating in a report on Tuesday, July 9th. One analyst […]